Evidence map›Paper›PMID 35768779›Full record

ArticleBMC cardiovascular disorders2022

Outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention or pharmacoinvasive strategy in a Latin American country.

Manuel Chacón-Diaz, Piero Custodio-Sánchez, Paol Rojas De la Cuba, Germán Yábar-Galindo, René Rodríguez-Olivares, David Miranda-Noé, Luis Marcos López-Rojas, Akram Hernández-Vásquez

Abstract read
In one paragraph

Article in BMC cardiovascular disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Manuel Chacón-DiazInstituto Nacional Cardiovascular INCOR, Essalud, Lima, Peru.
Piero Custodio-SánchezHospital Nacional Almanzor Aguinaga Asenjo, Essalud, Chiclayo, Peru.
Paol Rojas De la CubaHospital Nacional Guillermo Almenara, Essalud, Lima, Peru.
Germán Yábar-GalindoHospital Nacional Guillermo Almenara, Essalud, Lima, Peru.
René Rodríguez-OlivaresInstituto Nacional Cardiovascular INCOR, Essalud, Lima, Peru.
David Miranda-NoéInstituto Nacional Cardiovascular INCOR, Essalud, Lima, Peru.
Luis Marcos López-RojasHospital Nacional Alberto Sabogal, Essalud, Callao, Peru.
Akram Hernández-VásquezCentro de Excelencia en Investigaciones Económicas y Sociales en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. ahernandez@usil.edu.pe.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for ST-segment elevation myocardial infarction (STEMI). The pharmacoinvasive strategy (PIs) is a reasonable alternative when prompt PPCI is not possible, especially in resource-limited regions. We aimed to compare PPCI versus PIs outcomes in Peru.

methodsThis was a retrospective cohort study based on the second Peruvian Registry of STEMI (PERSTEMI II). We compared the characteristics, in-hospital outcomes and 30-day mortality of patients undergoing PPCI during the first 12 h and those receiving a PIs. A propensity score-matched analysis was conducted to compare the effects of each treatment strategy on clinical outcomes.

resultsPIs patients were younger than PPCI patients, had a shorter first medical contact time, first medical contact to reperfusion time, and total ischemic time until reperfusion. Successful PCI was more frequent in the PIs group (84.4% vs. 71.1%, p = 0.035). There were no differences between PIs and PPCI in terms of total in-hospital mortality (5.2% vs. 6.6%, p = 0.703), cardiovascular mortality (4.2% vs. 5.3%, p = 0.735), cardiogenic shock (8.3% vs. 13.2%, p = 0.326), heart failure (19.8% vs. 30.3%, p = 0.112), or major bleeding (0% vs. 2.6%, p = 0.194). In the propensity score-matched analysis, the rates of cardiovascular mortality, postinfarction heart failure and successful reperfusion were similar.

conclusionsIn this real-world study, no differences were found in the in-hospital outcomes between patients with STEMI who received PIs or PPCI.

Indexed as

Heart FailurePercutaneous Coronary InterventionST Elevation Myocardial InfarctionFibrinolytic AgentsHumansLatin AmericaRetrospective StudiesThrombolytic TherapyTreatment OutcomeFibrinolytic AgentsHeart failureMortalityMyocardial infarctionPeruReperfusion

Identifiers

PMID35768779
PMCPMC9244071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.